Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

BACKGROUND: Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties are overcome through re-bridging of the inter-chain...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Greene, Michelle K., Chen, Ting, Robinson, Eifion, Straubinger, Ninfa L., Minx, Charlene, Chan, Darren K. W., Wang, Jun, Burrows, James F., Van Schaeybroeck, Sandra, Baker, James R., Caddick, Stephen, Longley, Daniel B., Mager, Donald E., Straubinger, Robert M., Chudasama, Vijay, Scott, Christopher J.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653048/
https://ncbi.nlm.nih.gov/pubmed/32913288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01046-6
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker